SCHEMBL2684512

SCHEMBL2684512

N[C@@H](Cc1ccccc1)C(=O)Nc1cc(C(=O)O)cc(-c2ccncc2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR142 Q7Z601 10/20 0.62
AKT1 P31749 1/20 0.56
CIT O14578 1/20 0.48
ROCK2 O75116 5/20 0.48
ROCK1 Q13464 4/20 0.48
RPS6KA5 O75582 1/20 0.46
RPS6KA4 O75676 1/20 0.46
PRKACA P17612 1/20 0.46
MAPK1 P28482 1/20 0.46
GSK3A P49840 1/20 0.46
GSK3B P49841 1/20 0.46
IRAK1 P51617 1/20 0.46
PRKX P51817 1/20 0.46
PRKG1 Q13976 1/20 0.46
PKN2 Q16513 1/20 0.46
CLK4 Q9HAZ1 1/20 0.46
SGK2 Q9HBY8 1/20 0.46
AAK1 Q2M2I8 1/20 0.46
CDK2 P24941 1/20 0.46
CDK7 P50613 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2684514 1.00 GPR142 (0.62) GPR142AKT1CITROCK2ROCK1
SCHEMBL2684698 0.85 GPR142 (0.61) GPR142AKT1CITROCK2ROCK1
SCHEMBL2684701 0.85 GPR142 (0.61) GPR142AKT1CITROCK2ROCK1
SCHEMBL2802584 0.84 ROCK2 (0.64) GPR142AKT1CITROCK2ROCK1
SCHEMBL10260826 0.84 ROCK2 (0.64) GPR142AKT1CITROCK2ROCK1
SCHEMBL2802593 0.84 ROCK2 (0.64) GPR142AKT1CITROCK2ROCK1
Hydrochloric Acid SCHEMBL4525075 0.83 ROCK2 (0.62) GPR142AKT1CITROCK2ROCK1
SCHEMBL2684586 0.82 GPR142 (0.53) GPR142AKT1CITROCK2ROCK1
SCHEMBL9590958 0.81 AKT1 (0.66) GPR142AKT1CITROCK2ROCK1
SCHEMBL2684203 0.79 GPR142 (0.55) GPR142ROCK2ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 US claimed
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 US disclosed
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 US disclosed
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2012-05-10 US disclosed
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2012-05-10 US disclosed
WO-2010093849-A2 PHENYLALANINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2010-08-19 WO disclosed
WO-2010093849-A2 PHENYLALANINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2010-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS IAPP, INSR, AMY2A GPR142 2779/4885AKT1 2566/4885CIT 3081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.